SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is seeing significant buzz after delivering strong earnings driven by explosive demand for its AI cloud infrastructure, with a massive surge in future revenue obligations affirming the AI build-out and prompting community discussion about a potential major stock rebound.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after reporting its first-ever quarterly net profit and robust Q1 delivery guidance, driving strong community excitement about its undervalued EV ecosystem, advanced chip technology, and the potential for a significant short squeeze.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is highly anticipated ahead of its earnings report, fueled by its recent AIUC-1 certification for secure AI agents. This has intensified a polarized community debate, with bulls expecting a significant short squeeze and fundamental growth in Agentic AI, while bears highlight competition and recent price weakness.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending amid extreme volatility driven by conflicting reports on the Strait of Hormuz, including a retracted US Navy escort claim and intelligence of Iran deploying mines. This uncertainty, coupled with the International Energy Agency's proposed release of strategic oil reserves, has fueled widespread community debate over perceived market manipulation and future oil prices.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace ($FLY) is trending due to immense community anticipation for its upcoming Alpha Flight 7 launch and its recent selection for the multi-billion dollar SHIELD defense contract, though repeated launch delays and uncertainty around its earnings are also prominent discussion points. Amidst this, the company's strategic SciTec acquisition to bolster its defense technology capabilities is a key focus for investors eyeing long-term growth in the booming space sector.

goeasy Ltd. engages in the provision of non-prime leasing and lending services. The company was founded by Gordon J. Reykdal on December 14, 1990 and is headquartered in Mississauga, Canada.

Goeasy Ltd

Goeasy Ltd. is under intense scrutiny following the suspension of its dividend and withdrawal of its outlook, which has intensified concerns over loan mismanagement, especially within its auto lending division, and is seen by some as validating a prior short seller report. The community is sharply divided, with discussions ranging from fears of "bad management" and potential bankruptcy amidst broader subprime market challenges to beliefs that the market is "overreacting," creating a "generational buying opportunity."

SSgA Active Trust - State Street Real Estate Select Sector SPDR ETF

Real Estate Select Sector SPDR Fund

XLRE is trending as rising Treasury yields, fueled by geopolitical tensions, create headwinds for the real estate sector, though the community remains divided between those anticipating eventual rate cuts and concerns over prolonged higher rates impacting housing and commercial real estate.

ProShares Trust - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

UCO is trending amidst heightened Middle East tensions where ongoing conflict involving Iran is threatening crude oil supply through the Strait of Hormuz, driving a significant war premium. However, the market remains volatile as the community debates this against a substantial planned strategic petroleum reserve release and existing global oversupply pressures.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as the community eagerly anticipates groundbreaking Phase 3 REGAL trial results for its AML therapy, interpreting ongoing developments and CEO comments as signals for potential 'curative outcomes' and a significant buyout, fueling intense discussion and a belief in a substantial short squeeze despite some external skepticism.

Ucore Rare Metals, Inc. Is a technology company, which engages in the business of metal separation products, and services to the mining and mineral extraction industry. Its projects include Bokan-Dotson Ridge Rare Earth Element. The company was founded on October 5, 2006 and is headquartered in Halifax, Canada.

Ucore Rare Metals Inc

Ucore Rare Metals Inc.

Ucore Rare Metals is trending as its RapidSX technology, proven efficient in separating rare earths, positions it as a critical solution for secure Western supply chains. Strong U.S. and Canadian government backing, along with the impending commercial production at its Louisiana facility, fuels investor optimism for this vital defense and EV component processor.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 PR Newswire SALT LAKE CITY, March 10...

Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?

Lipocine (LPCN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates

Relay Therapeutics (RLAY) delivered earnings and revenue surprises of +16.51% and -52.91%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for...

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN...

Lipocine Inc. (NASDAQ:LPCN) Short Interest Update

Lipocine Inc. (NASDAQ:LPCN - Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totaling 157,602 shares...

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) Lipocine Reports Encouraging Progress Post Second Interim Safety...

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone PR Newswire SALT LAKE CITY, Dec. 16, 2025 Second Drug...

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in...

Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates

Lipocine (LPCN) delivered earnings and revenue surprises of -5.36% and +15.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

LPCN
Lipocine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LPCN News

LPCNLipocine Inc